These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38968479)

  • 1. Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease: Systematic review and meta-analysis.
    Zhang Z; Zhang X; Xu L
    Medicine (Baltimore); 2024 Jul; 103(27):e35663. PubMed ID: 38968479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
    Gareri P; Cotroneo A; Lacava R; Seminara G; Marigliano N; Loiacono A; De Sarro G
    Arch Gerontol Geriatr Suppl; 2004; (9):207-15. PubMed ID: 15207416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara.
    Chiabrando G; Bianchi S; Poluzzi E; Montanaro N; Scanavacca P
    Eur J Clin Pharmacol; 2010 Jul; 66(7):661-9. PubMed ID: 20464383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.
    Zhu L; Wu G; Heng W; Zang X
    Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2053-2057. PubMed ID: 34862873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.
    Yoshida K; Roberts R; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):708-716. PubMed ID: 28215900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
    Deberdt WG; Dysken MW; Rappaport SA; Feldman PD; Young CA; Hay DP; Lehman DL; Dossenbach M; Degenhardt EK; Breier A
    Am J Geriatr Psychiatry; 2005 Aug; 13(8):722-30. PubMed ID: 16085789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone versus olanzapine for schizophrenia.
    Jayaram MB; Hosalli P; Stroup S
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005237. PubMed ID: 16625629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
    Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
    N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
    Schneider LS; Dagerman K; Insel PS
    Am J Geriatr Psychiatry; 2006 Mar; 14(3):191-210. PubMed ID: 16505124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
    Yunusa I; Rashid N; Demos GN; Mahadik BS; Abler VC; Rajagopalan K
    Adv Ther; 2022 May; 39(5):1993-2008. PubMed ID: 35247186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
    Yunusa I; Alsumali A; Garba AE; Regestein QR; Eguale T
    JAMA Netw Open; 2019 Mar; 2(3):e190828. PubMed ID: 30901041
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.